Antibiotice Sa · BVB:ATB
Antibiotice Sa — H1 2019 Earnings Presentation
15 slides from Antibiotice Sa's earnings presentation, December 2019
Slide 1: Prezentare companie
a+ ot GF ” Antibiotice ta si suflet
Slide 2: Tradition means continuity and recognition
Tradition means continuity and recognition Write it➢here 1955 Only a decade after the synthesis of Penicillin, Antibiotice began its activity and became the first producer of this active substance in Romania and in South-East Europe. ➢ 1995-1990 The manufacturing structure has developed, especially
Slide 3: Antibiotice SA on the capital market
Antibiotice SA on the capital market Write it here Investors MINISTERUL SANATATII (*) S.I.F. OLTENIA (*) BROADHURST INVESTMENTS LIMITED 53.0173 53.0173 S.I.F. TRANSILVANIA S.I.F. BANAT-CRISANA S.A. 18.8999 18.8999 15.8753 A - INVEST 15.8753 4.1977 4.1977 FOND DE PENSII ADMINISTRAT PRIVAT 0.3333 0.33
Slide 4: Antibiotice SA in the pharmaceutical market in Romania
Antibiotice SA in the pharmaceutical market in Romania Write it here ❑ During the first semester of 2019 the value of the company's sales was RON 167 million (15.9% of the relevant market), experiencing an increase by +1% compared to the similar period of 2018; ❑ The prescription products (RX) accou
Slide 5: A partner of the health system in Romania
A partner of the health system in Romania Write it here Our company is present in all over the 500 hospitals and in over 4000 pharmacies in Romania; 37 of medicinal products considered essential by the WHO for the treatment of patients are manufactured in the city of Iasi; Our company permanently pr
Slide 6: The production of Antibiotice
The production of Antibiotice Write it here During the first semester of 2019 Antibiotice has manufactured: • 320 million pharmaceutical units in the form of tablets, capsules, parenteral products, topical products (ointments, creams, gels), suppositories and pessaries; • During the first semester o
Slide 7: Research & Development
Research & Development Write it here ➢ In 2019 the research product pipeline includes a number of 15 projects, of which: 1 injectable product, 4 projects of topical forms and 10 projects of solid oral forms. These projects cover the therapeutic classes that define the portfolio of Antibiotice: oral
Slide 8: The export increased by 6.34% compared to the similar period of 2018
The export increased by 6.34% compared to the export made Write it here during the similar period of 2018 SEM I SEM I Variation TYPE OF PRODUCT 2018 2019 % NYSTATIN 36,129,359 38,715,323 7.16% FINISHED PRODUCTS 31,852,655 33,575,462 5.41% TOTAL (LEI) 67,982,014 72,290,784 6.34% The main development
Slide 9: Together we create value
Together we create value Write it here THE STRUCTURE OF THE STAFF ON 30.06.2019 Total employees 1415 608 higher 807 secondary education education employees 43% employees 57% Structure of the higher education staff 10.1% 3.2% 15.8% Medici,farmacişti Ingineri chimişti, chimişti, fizicieni 7.8% Economi
Slide 10: We are responsible for people, community and environment
We are responsible for people, community and environment Write it here We manufacture medicinal products with science, but at the same time we put our soul into what we do to always stay close to people. Antibiotice assumes the responsibility to contribute as a "good citizen" to the life of the comm
Slide 11: The situation of the overall result
The situation of the overall result During Write it herethe first semester of 2019, compared to the similar period of the previous year and following the strategic objectives with focus on the internationalization of the business, the sales revenues experienced an increase of 9%, due mainly to the i
Slide 12: Statement of financial position
Statement of financial position Write it here Financial period 30.06.2019/31.12.2018 31.12.2018 30.06.2019 0 1 2 3=2/1 ASSETS FIXED ASSETS Tangible fixed assets 310.640.665 316.959.046 1,02 Intangible fixed assets 15.028.716 16.134.982 1,07 TOTAL FIXED ASSETS 325.669.381 333.094.028 1,02 CURRENT ASS
Slide 13: Long-term liabilities and equity
Write it here Financial period 30.06.2019/31.12.2018 31.12.2018 30.06.2019 0 1 2 3=2/1 TOTAL LONG-TERM LIABILITIES 54.419.154 61.236.387 1,13 TOTAL LIABILITIES 233.377.868 253.419.044 1,09 Share capital and reserves Share capital 264.835.156 264.835.156 1,00 Revaluation reserves 53.459.597 52.110.02
Slide 14: Operational indicators
Write itOperational here indicators Indicators Calculation method Unit of measure 30.06.2018 30.06.2019 Indicators Calculation method Unit of measure 30.06.2018 30.06.2019 Current liquidity Current assets /Current liabilities number of times 2.04 2.11 Level of indebtedness Borrowed capital / Equity
Slide 15: Thank You! Q & A
Thank You! Q&A 2015